We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Change of Nerve Conduction Properties in IVIg Dependent Neuropathies

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by Helmar Lehmann, University of Cologne.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01655394
First Posted: August 1, 2012
Last Update Posted: December 12, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Helmar Lehmann, University of Cologne
July 30, 2012
August 1, 2012
December 12, 2014
October 2012
December 2014   (Final data collection date for primary outcome measure)
Clinical Improvement [ Time Frame: 6 Months ]
Not Provided
Complete list of historical versions of study NCT01655394 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
IVIg exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction in patients with immune-mediated neuropathies will be explored.
IVIg exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction in patients with immune-mediated neuropathies will be explored
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Serum
Probability Sample
patients with immune neuropathies
  • Guillain-Barre Syndrome
  • CIDP
  • Multifocal Motor Neuropathy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
50
June 2016
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • immune neuropathy
  • age above 18 y
  • IVIg treatment

exclusion:

  • no IVIg treatment
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01655394
01607831337
No
Not Provided
Not Provided
Helmar Lehmann, University of Cologne
University of Cologne
Not Provided
Principal Investigator: Helmar C. Lehmann, PD Dr. med. PI
University of Cologne
December 2014